Sinaptica Therapeutics

Company Overview


Sinaptica is a pioneering neurotechnology company dedicated to advancing brain health and cognitive longevity through deep tech innovation. Positioned at the intersection of neuroscience, artificial intelligence, and healthcare infrastructure, Sinaptica develops scalable solutions that enhance neural performance and mitigate age-related cognitive decline. The company’s mission aligns with the broader Healthy Aging movement by delivering data-driven, personalized interventions designed to extend healthy brain function throughout the lifespan. By integrating proprietary neuroimaging analytics, machine learning algorithms, and therapeutic platforms, Sinaptica is reshaping the future of neurocare and longevity.

Scientific foundations:

Personalized neuromodulation for Alzheimer’s – the brain reveals its bioelectric secrets

A conversation with Emiliano Santarnecchi, PhD
Sinaptica Co-Founder

Associate Professor of Neurology & Radiology,
Harvard Medical School; Director, Precision Neuroscience and Neuromodulation Program at Massachusetts General Hospital.

Investment Recommendation

We are excited to share with you the opportunity to co-invest with 1004 Venture Partners in Sinaptica Therapeutics, a clinical-stage neuromodulation therapeutics company leading the development of a new class of novel personalized therapeutics to revolutionize the treatment of Alzheimer’s and other primary neurodegenerative diseases. 

Recommentaions

Sinaptica's innovative breakthrough therapy, supported by compelling Phase 2 clinical efficacy data across four FDA-agreed endpoints and without concerning side effects, presents a strong investment opportunity. We encourage you, as accredited investors, to join us in supporting their convertible note investment. The next steps involve confirming these clinical study results in a pivotal study and achieving commercial readiness. 

We plan to participate in Sinaptica's current convertible note as the company develops its program and prepares for pivotal trials in 2025. Additionally, we are interested in participating in the Series A priced equity round, which is expected to close in the second half of 2025. 

Highlights

  • Clinical Efficacy: A year-long Phase 2 study demonstrated a significant 44%-87% slowdown in cognitive decline for patients with mild-to-moderate Alzheimer’s, achieving statistical significance across all clinical endpoints. This represents a highly effective treatment option, compared to competitors through existing treatments and recently approved monoclonal antibodies with marginal efficacy (26-32%) with burdensome safety concerns.

  • Strategic Partnership: An exclusive distribution Letter of Intent (LOI) has been signed with Nexstim, the provider of the hardware stimulation device. This partnership is projected to generate an estimated $6.3 million in the first two years of operations.

  • Advanced Stage at Seed Round: The company is uniquely positioned as a Phase 2 complete company at the seed stage, a result of over $5 million in non-dilutive funding and the collaboration with Nexstim for hardware.

  • Exceptional Leadership Team: The founding team includes a Director of Noninvasive Brain Stimulation at Saint Lucia Foundation (and Univ. of Ferrara professor) and a Director of Precision Neuroscience at MGH (and Harvard professor). The CEO previously led Boston Scientific’s $1 billion NeuroMod division, with key VPs from Neuronetics (R&D) and Functional Neuromod (Clinical, Phase 3 trials).

  • Strong Intellectual Property: A broad US patent has been granted for TMS-EEG personalization across various diseases, with potential for expansion to other conditions. A diagnostic patent for biomarkers has also been published.

  • Regulatory & Commercial Outlook: Regulatory approvals and commercial launches are anticipated to commence in 2029/2030.

  • Notable Investors: This funding round is supported by Keiretsu Forum, HealthTech Capital, the CEO of SetPoint Medical, the CEO of NevGen, and a Boston Scientific executive. The existing cap table includes prominent investors such as Sony, Time Zero Capital (Lynk Global), and the Daly family (Time Warner). Note holders include Bootstrap Ventures, Pureland Ventures, and several biotechnology CEOs and other High Networth investors.

This development signifies a potential paradigm shift in fighting debilitating diseases. It powerfully illustrates how innovative machine learning and AI can unlock new avenues for precision medicine. By leveraging sophisticated algorithms and vast datasets, this technology identifies subtle patterns and develops highly targeted treatments, moving us closer to personalized healthcare.

Meet the Team

  • Giacomo Koch, MD, PhD

    Co-founder and Scientific Advisor

    Full Professor of Human Physiology at Università degli Studi di Ferrara

    Director, Noninvasive Brain Stimulation Laboratory, Santa Lucia Foundation

  • Co-Founder

    Emiliano Santanecchi, PhD

    Co-Founder and Scientific Advisor

    Associate Professor of Neurology and Radiology at Harvard Medical School

    Director, Precision Neuroscience and Neuromodulation Program at Massachusetts General Hospital

    Faculty - Mind Brain Behavior Interfaculty Program at Harvard University

  • Rich Macary

    President

    Healthcare Executive in Biotech and Med Device

    Ex-VP of BD, Serepta

    Chief Strategy, Delos Ventures

    Owner, Macary Advisors, Inc.

  • Ken Mariash

    Chief Executive Officer

    Medtech & Biopharma Marketing, Strategy, and Corp Dev Executive

    Former Head of Strategy, Boston Scientific Neuromodulation

    Former Global Franchise GM, Cosman Medical

More Details

Sinaptica provides personalized weekly non-invasive rTMS-EEG brain stimulation for Alzheimer's by utilizing a patented non-invasive approach to treating Alzheimer’s via precision neurostimulation of a key brain network involved in memory, the Default Mode Network (DMN). Sinaptica’s world-renowned scientific co-founders - Giacomo Koch, MD, PhD, University of Ferrara, and Emiliano Santarnecchi, PhD, Harvard Medical School - pioneered research on this novel approach, which a growing body of evidence indicates can slow disease progression.

Materials

Deck: 

Video:  

Supporting Papers:

Media:

Capital Raise

The Company is now preparing for pivotal studies and is currently raising capital via a convertible note and a Series A equity round (in 2H 2025) to advance the technology application towards market approval in the United States and elsewhere. 1004 VP has secured a $500k allocation into this convertible note with the condition of preferred stock conversion at the Series A round at $55m pre-money valuation cap and 20% discount, convertible upon $5M or more in equity financing, or payable in 2 years at 6%. This note will provide funds for completing another Phase 2 study (in Italy) and another Phase 2 multi-site study in the US, and further development of the clinical device.

Return Potential: 

5-6 Year Revenue Projections: ~$260M - $500M

Exit Range: $1.3B - $4.8B

Revenue Multiple

  • Non Pro-rata 48x - 160x.

  • Pro-rata 13x - 48x

Deadline: The deadline for submitting your investment commitment, signing docs, and sending your wire is Thursday, July 31st, 2025.

Terms of 1004VP’s Investor Syndicate:

A 2% annual management fee for 5 years, which is collected upfront and then drawn down annually over a 5 year period to cover operating expenses and fund admin expenses. Upon a liquidity event in less than 5 years any remaining management fee that has not been drawn down is returned to investors. There is also a 20% carried interest on net profits.

Confidential Information:

All information contained in this page and linked to in this page are confidential and are not to be shared outside of 1004VP's Investor Syndicate investors and LPs in 1004VP Fund I.  If you're interested in sharing this opportunity with other accredited investors in your network you must get approval from 1004 Venture Partners before sharing.

Next

Deka Bioscience